Compare STTK & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | VSAT |
|---|---|---|
| Founded | 2016 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 5.6B |
| IPO Year | 2020 | 1996 |
| Metric | STTK | VSAT |
|---|---|---|
| Price | $3.91 | $48.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $6.20 | ★ $43.60 |
| AVG Volume (30 Days) | 683.9K | ★ 2.0M |
| Earning Date | 03-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $4,616,074,000.00 |
| Revenue This Year | N/A | $5.25 |
| Revenue Next Year | N/A | $3.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.07 |
| 52 Week Low | $0.69 | $7.36 |
| 52 Week High | $4.89 | $49.68 |
| Indicator | STTK | VSAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 58.00 |
| Support Level | $3.76 | $43.87 |
| Resistance Level | $4.23 | $47.98 |
| Average True Range (ATR) | 0.30 | 3.50 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 51.06 | 75.17 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.